Table 4 Subgroup analysis for the prevalence of venous thromboembolism in ovarian cancer patients receiving chemotherapy
Subgroups | No. of studies | Pooled rate with 95% CI | I2 (%) |
|---|---|---|---|
The overall pooled result | 11 | 0.09 (0.06, 0.12) | 88.9 |
Publication time | |||
≤ 2009 | 3 | 0.06 (0.02, 0.09) | 89.9 |
> 2010 | 8 | 0.10 (0.08, 0.12) | 22.8 |
Region | |||
Asia | 2 | 0.11 (0.07–0.15) | 40 |
Europe | 6 | 0.08 (0.04–0.12) | 88.9 |
The USA | 3 | 0.09 (0.06–0.13) | 38.9 |
Disease status | |||
Ovarian cancer | 5 | 0.10 (0.07–0.12) | 52.7 |
Advanced ovarian cancer | 4 | 0.08 (0.02–0.14) | 85.4 |
Recurrent ovarian cancer | 2 | 0.08 (0.03–0.13) | 15.3 |
Operation type | |||
Debulking surgery | 6 | 0.08 (0.04–0.12) | 85.7 |
Radical surgery | 5 | 0.10 (0.07–0.13) | 65.7 |
Sample size | |||
≤ 500 | 9 | 0.10 (0.08–0.12) | 22.2 |
> 500 | 2 | 0.05 (0.01–0.09) | 92.6 |
VTE diagnostic criterion | |||
Self-definition | 8 | 0.10 (0.08–0.12) | 27.6 |
CTC | 3 | 0.05 (0.01–0.10) | 87.5 |
Study design | |||
Case-control | 6 | 0.09 (0.05–0.13) | 91.9 |
Cross-sectional study | 2 | 0.08 (0.05–0.12) | 0 |
Retrospective cohort | 3 | 0.10 (0.06–0.14) | 55.6 |
NOS score | |||
≤ 6 | 2 | 0.08 (0.05–0.12) | 0 |
> 6 | 9 | 0.09 (0.06–0.12) | 90.4 |